

## Selected Innovative Medicines in Development as of January 21, 2026



# Oncology (1 of 3)

## AKEEGA (niraparib/abiraterone)

M1 Metastatic Castration-Sensitive Prostate Cancer (AMPLITUDE)

## IMBRUVICA (ibrutinib)

Frontline Mantle Cell Lymphoma (Triangle)

## RYBREVANT (amivantamab)

Subcutaneous (PALOMA-3)

## CARVYKTI (Ciltacabtagene autoleucel)

Frontline Multiple Myeloma TNI (CARTITUDE-5)

## ERLEADA (apalutamide)

High Risk Prostate Cancer (PROTEUS)

## JNJ-1900 (NBTXR3)

Head and Neck Cancer

## RYBREVANT (amivantamab)

Colorectal Cancer 2L (ORIGAMI-3)

## TALVEY (talquetamab)

Relapsed Refractory Multiple Myeloma A-CD38 Naïve (MonumenTAL-3)

## DARZALEX (daratumumab)

Smoldering Multiple Myeloma (AQUILA)

## INLEXZO (gemcitabine intravesical delivery system)

Non Muscle Invasive Bladder Cancer (SunRISe-1)

## TECVAYLI (teclistamab)

Multiple Myeloma 1-3PLs (MajesTEC-3)

## CARVYKTI (Ciltacabtagene autoleucel)

Frontline Multiple Myeloma Transplant Eligible vs ASCT (CARTITUDE-6)

## INLEXZO (gemcitabine intravesical delivery system)

Non Muscle Invasive Bladder Cancer BCG-naïve High Risk (SunRISe-3)

## pasritamig

Prostate Cancer

## RYBREVANT (amivantamab)

Head and Neck Cancer (ORIGAMI-5)

## TALVEY (talquetamab)

Relapsed Refractory Multiple Myeloma CD38 exposed (MonumenTAL-6)

## DARZALEX (daratumumab)

Frontline multiple myeloma transplant ineligible (CEPHEUS)

## RYBREVANT (amivantamab)

Frontline Non Small Cell Lung Cancer in combination with chemotherapy (PAPILLON)

## Bleximab

Newly Diagnosed AML, chemo ineligible in combination with Venetoclax and Azacitidine (cAMeLot-2)

## ERLEADA (apalutamide)

Localized Prostate Cancer (ATLAS)

## INLEXZO (gemcitabine intravesical delivery system)

High Risk Non Muscle Invasive Bladder Cancer BCG Experienced (SunRISe-5)

## RYBREVANT (amivantamab)

Colorectal Cancer (ORIGAMI-2)

## TALVEY + TECVAYLI

Relapsed Refractory Multiple Myeloma CD38 exposed (MonumenTAL-6)

## TALVEY (talquetamab)

TIE NDMM in combination with DR (MajesTEC-7)

**TAR-210 (erdafitinib intravesical delivery system)**  
Non Muscle Invasive Bladder Cancer (MoonRISe-1)

**TECVAYLI (teclistamab)**  
TIE NDMM in combination with DR (MajesTEC-7)

**JNJ-0683 (ARX788)**  
Breast Cancer

**JNJ-0387**  
Solid Tumors

**JNJ-2638**  
Gastrointestinal Cancer

**JNJ-4496**  
Hematological Malignancies

**JNJ-4916**  
Lung Cancer

**JNJ-8177 (ARX517)**  
Prostate Cancer

**TAR-210 (erdafitinib intravesical delivery system)**  
High Risk Non Muscle Invasive Bladder Cancer (MoonRISe-3)

**TECVAYLI (teclistamab)**  
Relapsed Refractory Multiple Myeloma CD38 exposed (MajesTEC-9)

**JNJ-1900 (NBTXR3)**  
Lung Cancer

**JNJ-1493**  
Hematological Malignancies

**JNJ-2761**  
Multiple Myeloma

**JNJ-4680**  
Lung Cancer

**JNJ-5322**  
Multiple Myeloma

**JNJ-8377**  
Lymphoma

**TECVAYLI (teclistamab)**  
TE NDMM maintenance (MajesTEC-4)

**bleximab**  
Relapsed Refractory Acute Myeloid Leukemia (cAMeLot-1)

**TALVEY + TECVAYLI**  
Relapsed Refractory Multiple Myeloma (RedirecTT-1)

**JNJ-2175**  
Solid Tumors

**JNJ-3413**  
Lymphoma

**JNJ-4681**  
Hematological Malignancies

**JNJ-7446**  
Lung Cancer

**JNJ-8543**  
Hematological Malignancies

**JNJ-9401**

Prostate Cancer

**JNJ-9530**

Hematological Malignancies

**JNJ-9892**

Hematological Malignancies

**JNJ-9968**

Hematological Malignancies

## icotrokinra

Psoriasis (ICONIC)

## STELARA (ustekinumab)

Pediatric Ulcerative Colitis (UNIFI JR)

## TREMFYA (guselkumab)

Psoriatic Arthritis Structural Damage (APEX)

## icotrokinra

Ulcerative Colitis (ICONIC-UC)

## nipocalimab

Sjogren's Disease

## TREMFYA (guselkumab)

Pediatric Crohn's Disease (MACARONI-23)

## JNJ-4804 Co-antibody Therapy

Ulcerative Colitis

## JNJ-5939

Atopic Dermatitis

## SIMPONI (golimumab)

Pediatric Ulcerative Colitis (PURSUIT 2)

## STELARA (ustekinumab)

Pediatric Juvenile Psoriatic Arthritis

## TREMFYA (guselkumab)

Ulcerative Colitis Subcutaneous Induction (ASTRO)

## icotrokinra

Psoriatic Arthritis (ICONIC-PsA)

## nipocalimab

Hemolytic Disease of the Fetus and Newborn (AZALEA)

## TREMFYA (guselkumab)

Pediatric Ulcerative Colitis (QUASAR JR)

## JNJ-4804 Co-antibody Therapy

Psoriatic Arthritis

## nipocalimab

Systemic Lupus Erythematosus

## STELARA (ustekinumab)

Pediatric Crohn's Disease (UNITI JR)

## TREMFYA (guselkumab)

Pediatric Psoriasis (PROTOSTAR)

## TREMFYA (guselkumab)

Pediatric Juvenile Psoriatic Arthritis

## nipocalimab

Warm Autoimmune Hemolytic Anemia (ENERGY)

## nipocalimab

Fetal and Neonatal Alloimmune Thrombocytopenia (FREESIA)

## icotrokinra

Crohn's Disease (ICONIC-CD)

## JNJ-4804 Co-antibody Therapy

Crohn's Disease

## nipocalimab

Idiopathic Inflammatory Myopathy

## Immunology (2 of 2)

---

**JNJ-5108**

Immunological Diseases

**JNJ-6848**

Immunological Diseases

**JNJ-7528**

Atopic Dermatitis

**JNJ-8638**

Immunological Diseases

## CAPLYTA (lumateperone)

Adjunctive Treatment for Major Depressive Disorder

## CAPLYTA (lumateperone)

Bipolar Mania

## RPGR Gene Therapy

Retinitis Pigmentosa (LUMEOS)

## ITI-1284

Alzheimer's Disease-Related Psychosis

## JNJ-2056 (tau active immunotherapy) \*

Alzheimer's Disease (RETAIN)

## IMAAVY (nipocalimab)

Generalized Myasthenia Gravis (Vivacity MG3)

## CAPLYTA (lumateperone)

Pediatric Psychiatric Indications

## seltorexant

Adjunctive Treatment for Major Depressive Disorder with  
Insomnia Symptoms (OARS)

## ITI-1284

Alzheimer's Disease-Related Agitation

## JNJ-5120

Major Depressive Disorder

## IMAAVY (nipocalimab)

Generalized Myasthenia Gravis Pediatrics (VIBRANCE MG)

## nipocalimab

Chronic Inflammatory Demyelinating Polyneuropathy  
(ARISE)

## ITI-1284

Generalized Anxiety Disorder

## JNJ-1887 sCD59

Geographic Atrophy

## SPRAVATO (esketamine)

Major Depressive Disorder with Suicidal Ideation  
Pediatrics

# Select Other Areas

---

## CABENUVA

HIV Adolescents

## milvexian (Factor Xla)

Secondary Stroke Prevention

## SIRTURO

Tuberculosis Long Acting

## UPTRAVI (selexipag)

Pediatric Pulmonary Arterial Hypertension (SALTO)

## milvexian (Factor Xla)

Atrial Fibrillation

## macitentan

Pulmonary Arterial Hypertension 75mg (UNISUS)

## SIRTURO

Leprosy

\*This is not a fully exhaustive list of all pipeline programs and assets. The pipeline includes assets currently progressing through clinical trials as well as those under review by regulatory bodies. Inclusion in the pipeline is based on the current status of these programs and assets and does not guarantee continued investment. This information is as of January 21, 2026 to the best of the Company's knowledge. Johnson & Johnson assumes no obligation to update this information. \*AC Immune ACI-35.030. Strategic Partnerships, Collaborations, and Licensing arrangements -milvexian: Bristol Myers Squibb; AAV-RPGR: UCL Business Plc; JNJ-1887: Hemera Biosciences; Long acting HIV injectable treatment regimen of rilpivirine and cabotegravir: ViiV Healthcare; REMICADE and SIMPONI/SIMPONI ARIA: Schering-Plough (Ireland) Company, a subsidiary of Merck & Co., Inc. and Mitsubishi Tanabe Pharma Corporation; TREMFYA: MorphoSys AG; JNJ-2113: Protagonist Therapeutics; Tau Immunotherapy: AC Immune SA; IMBRUVICA: Pharmacyclics, LLC, an AbbVie company; ZYTIGA: BTG International; DARZALEX and DARZALEX FASPRO: Genmab A/S; ERLEADA: Regents of California and Memorial Sload Kettering; CARVYKTI: Legend Biotech; AKEEGA: TESARO, an oncology-focused business within GSK; lazertinib: Yuhan Corporation; Duobody Platform bispecific antibody programs: Genmab A/S; ENHANZE platform; Halozyme Therapeutics; XmAb CD28 bispecific antibodies; Xencor; iPSC-derived chimeric antigen receptor (CAR) NK and CART-cell product candidates: Fate Therapeutics; UPTRAVI and OPSUMIT: Nippon Shinyaku (co-promotion in Japan); CD20-directed autologous CAR-Ts: Cellular Biomedicine Group, Inc. (CBMG); muscarinic M1 receptor antagonist: Pipeline Therapeutics; NBTXR3: Nanobiotix; A2a Receptor Antagonist: AdoRx Therapeutics Limited